

**NEUROSURGICAL RESEARCH
FOUNDATION INCORPORATED**

**FINANCIAL REPORT
FOR THE YEAR ENDED
31 MARCH 2023**

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2023

	Note	2023 \$	2022 \$
Research Fund			
Income			
Donations and fundraising	2	1,563,606	776,784
Investment income		9,343	11,288
Total income		<u>1,572,950</u>	<u>788,072</u>
Less expenses			
Research grants expenditure	4	401,898	1,054,988
Surplus (deficit)		<u>1,171,052</u>	<u>(266,916)</u>
Scholarships Fund			
Income			
Donations and fundraising		200	20,097
Investment income		795	(5,645)
Total income		<u>995</u>	<u>14,452</u>
Less expenses			
Scholarship awards		(15,000)	-
Surplus (deficit)		<u>(14,005)</u>	<u>14,452</u>
Operations Fund			
Income			
Investment income		(125,280)	325,000
Membership		665	645
Government grants & wage subsidies		-	-
Total income		<u>(124,615)</u>	<u>325,645</u>
Less expenses			
Administration expenses	3	251,843	223,252
Surplus (deficit)		<u>(376,458)</u>	<u>102,393</u>
Total comprehensive income		<u><u>780,589</u></u>	<u><u>(150,071)</u></u>

The accompanying notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2023

	Note	2023 \$	2022 \$
Current assets			
Cash and cash equivalents		658,648	88,427
Inventories		500	500
Receivables		5,224	
Prepayments and accrued income		4,444	14,749
Total current assets		<u>668,816</u>	<u>103,676</u>
Non-current assets			
Office equipment and computer software		1,256	1,786
Managed investments		5,101,493	5,254,048
Investments		338,378	
Total non-current assets		<u>5,441,128</u>	<u>5,255,834</u>
Total assets		<u>6,109,943</u>	<u>5,359,510</u>
Current liabilities			
Payables		1,129	2,186
Unallocated research grants payable	5	249,213	300,233
Income in advance			2,837
Accrued expenses		24,703	3,737
Provisions		29,726	7,239
Total current liabilities		<u>304,771</u>	<u>316,232</u>
Non-current liabilities			
Provisions			18,695
Total non-current liabilities		<u>-</u>	<u>18,695</u>
Total liabilities		<u>304,771</u>	<u>334,927</u>
Net assets		<u>5,805,172</u>	<u>5,024,583</u>
Total accumulated funds		<u>5,805,172</u>	<u>5,024,583</u>

The accompanying notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
STATEMENT OF CHANGES IN ACCUMULATED FUNDS
FOR THE YEAR ENDED 31 MARCH 2023

	Year ended 31 March 2023			Total
	Research Fund	Scholarships Fund	Operations Fund	
Accumulated funds at beginning of year	634,667	195,758	4,194,158	5,024,583
Total comprehensive income	1,171,052	(14,005)	(376,458)	780,589
Accumulated funds at end of year	<u>1,805,719</u>	<u>181,753</u>	<u>3,817,700</u>	<u>5,805,172</u>
	Year ended 31 March 2022			Total
	Research Fund		Operations Fund	
Accumulated funds at beginning of year	601,583	136,204	4,436,867	5,174,654
Total comprehensive income	(266,916)	14,452	102,393	(150,071)
Transfer for Research fund	300,000		(300,000)	-
Transfer to Scholarships Fund		45,102	(45,102)	
Accumulated funds at end of year	<u>634,667</u>	<u>195,758</u>	<u>4,194,158</u>	<u>5,024,583</u>

The accompanying notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2023

	Note	2023 \$	2022 \$
Cash flows from operating activities			
Cash receipts from donations, fundraising & grants		1,306,985	821,501
Cash payments to suppliers and employees		(323,191)	(276,574)
Cash payments for research grants (net of returns)		(449,998)	(982,718)
Interest received		-	-
Investment income received		36,425	13,203
	6	<u>570,221</u>	<u>(424,588)</u>
Cash flows from investing activities			
(Additions) / withdrawals from investment portfolio		-	104,602
		<u>-</u>	<u>104,602</u>
Net increase/(decrease) in cash and cash equivalents		<u>570,221</u>	<u>(319,986)</u>
Cash and cash equivalents at beginning of year		88,427	408,413
Cash and cash equivalents at end of year		<u><u>658,648</u></u>	<u><u>88,427</u></u>

The accompanying notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

Note 1 Statement of significant accounting policies

This financial report is a special purpose financial report prepared in order to satisfy the financial reporting requirements of the Associations Incorporation Act 1985 and the Australian Charities and Not-for-profits Commission Act 2012. The Board has determined that the Foundation is not a reporting entity.

The financial report has been prepared in accordance with the requirements of the Associations Incorporation Act 1985 and the recognition and measurement aspects of all applicable Australian Accounting Standards, adopted by Australian Accounting Standards Board (AASB) and other authoritative pronouncements of the AASB that have a material effect. The financial report does not include the disclosure requirements of the following pronouncements;

AASB 7	Financial instruments: disclosures
AASB 8	Operating segments
AASB 102	Inventories
AASB 112	Income taxes
AASB 116	Property, plant and equipment
AASB 124	Related party disclosures
AASB 132	Financial instruments: presentations
AASB 137	Provisions, contingent liabilities and contingent sssets

The following accounting policies have been adopted in the preparation on the financial statements:

Basis of accounting

Dividend income and donations are recorded when received. Interest income is accounted for on an accruals basis. Expenses are accounted for net of GST when paid with input credits being refundable.

Income tax

The Foundation has been endorsed as an Income Tax Exempt Charity (ITEC) and a Deductible Gift Recipient (DGR).

Investments

Investments in the managed investment portfolio are valued at fair value at balance date being the market value of the portfolio held. Unrealised gains and losses arising from changes in the fair value of investments are recognized in the Statement of Comprehensive Income.

Employee benefits

Provision made for the foundation's liability for employee benefit arising from services rendered by employees to the end of the reporting period.

These notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

	2023 \$	2022 \$
Note 2 Donations and fundraising		
General		
Donations	334,507	375,818
Less: donation expenses	(17,855)	(14,921)
Bequests	1,161,709	21,796
Foundations & Trusts	-	351,990
Fundraising	151,315	29,618
Less: fundraising expenses	(70,109)	(11,197)
	<u>1,559,567</u>	<u>753,104</u>
Paediatric		
Donations	4,039	23,680
	<u>4,039</u>	<u>23,680</u>
	<u><u>1,563,606</u></u>	<u><u>776,784</u></u>
Note 3 Administration expenses		
Depreciation	530	763
Employee expenses and entitlements	211,127	172,579
Other administration expenses	40,186	49,910
	<u>251,843</u>	<u>223,252</u>
Note 4 Research grants expenditure		
NRF Chair of NeuroSurgical Research – Neurodegeneration	10,750	86,248
NRF Chair of NeuroSurgical Research – Stroke	35,195	43,000
NRF Chair of NeuroSurgical Research – SCI / TBI	80,465	242,741
Uni SA - Paediatric research	29,475	43,000
Uni SA - Brain Tumour Research	216,033	180,609
Flinders University - Brain Tumour Research	31,000	193,491
Royal Adelaide Hospital - Stroke		25,000
Royal Adelaide Hospital - Brain Tumour Research	50,000	43,000
Royal Adelaide Hospital - TBI		20,000
Royal Adelaide Hospital - Equipment		105,448
Unallocated research grants	(51,020)	72,451
	<u>401,898</u>	<u>1,054,988</u>

These notes form part of these financial statements

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

	2023	2022
	\$	\$
Note 5		
Unallocated research grants payable		
Opening balance	300,233	227,782
Current year expense - unallocated research grants	(51,020)	72,451
Closing balance	<u><u>249,213</u></u>	<u><u>300,233</u></u>
Note 6		
Reconciliation of total comprehensive income to cash flows from operating activities		
Total comprehensive income	780,589	(150,071)
Adjustments for:		
Non cash items		
(Revaluation)/devaluation of investments to fair value	156,791	(317,441)
Depreciation	530	763
Provisions	3,792	1,800
Bequests - non cash	(342,614)	-
Change in balance sheet accounts		
Decrease/(increase) in current assets	5,081	(12,996)
(Decrease)/increase in current liabilities	(33,948)	53,357
(Decrease)/increase in non-current liabilities	-	-
Net cash flow surplus/(deficit) from operating activities	<u><u>570,221</u></u>	<u><u>(424,588)</u></u>

These notes form part of these financial statements

**NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
STATEMENT BY MEMBERS OF THE BOARD**

The Board of Neurosurgical Research Foundation Incorporated has determined that the Foundation is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial statements. In the opinion of the Board, the financial report:

- 1 presents fairly the results of the operations of the Foundation for the financial year ended 31 March 2023 and the state of affairs of the Foundation as at the end of that financial year; and
- 2 the Board has reasonable grounds to believe that the Foundation will be able to pay its debts as and when they fall due.

This statement has been made in accordance with a resolution of the Board.

Dated this 14th day of June 2023



President – G McCulloch



Honorary Treasurer – T C Neill

**NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
REPORT OF THE BOARD**

In accordance with section 35(5) of the Associations Incorporation Act 1985 (as amended), the Board of Neurosurgical Research Foundation Incorporated hereby states that during the financial year ended 31 March 2023:

- (a)
 - (i) no officer of the Foundation;
 - (ii) no firm of which an officer is a member; and
 - (iii) no body corporate in which an officer has a substantial financial interest; has received, or become entitled to receive, a benefit as a result of a contract between the officer, firm or body corporate and the Foundation.
- (b) no officer of the Foundation has received directly or indirectly from the Foundation any payment or other benefit of a pecuniary value.

except for the following:

a salary, superannuation contributions and travelling allowances, paid in the ordinary course of business, to, or for the benefit of, the Executive Officer are included in the Operations Fund expenditure.

This report is made in accordance with a resolution of the Board.

Dated this 14th day of June 2023



President – G McCulloch



Honorary Treasurer – T C Neill

NEUROSURGICAL RESEARCH FOUNDATION INCORPORATED
RESPONSIBLE PERSONS' DECLARATION

(per section 60.15 of the Australian Charities and Not-for-profits Commission Regulation 2013)

The responsible persons declare that in the responsible persons' opinion:

- (a) there are reasonable grounds to believe that the registered entity is able to pay all of its debts, as and when they become due and payable; and
- (b) the financial statements and notes satisfy the requirements of the Australian Charities and Not-for-profits Commission Act 2012.

Signed in accordance with subsection 60.15(2) of the Australian Charities and Not-for-profit Commission Regulation 2013.



Tonleir

**Auditor's Independence Declaration under Section 60-40 of
the Australian Charities and Not-For-Profits Commission
Act 2012 to the Board Members of Neurosurgical Research
Foundation Incorporated**

I declare that, to the best of my knowledge and belief during the year ended 31 March 2023 there have been:

- no contraventions of the auditor independence requirements as set out in the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.



William Buck (SA)
ABN 38 280 203 274



G.W. Martinella
Partner

Dated this 24th of July 2023.

Neurosurgical Research Foundation Incorporated

Independent auditor's report to members

Report on the Audit of the Financial Statements

Opinion

We have audited the financial report of NeuroSurgical Research Foundation Incorporated (the Foundation), which comprises the statement of financial position as at 31 March 2023, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information, and the statement by the members of the Board.

In our opinion the financial report of NeuroSurgical Research Foundation Incorporated has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- a. giving a true and fair view of the Foundation's financial position as at 31 March 2023 and of its financial performance for the year then ended; and
- b. complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2022*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Foundation in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Foundation's financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of the Management and Those Charged with Governance for the Financial Report

The Board of the NeuroSurgical Research Foundation Incorporated are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The Board's responsibility also includes such internal control as the Board determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Board are responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board either intend to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

The Board are responsible for overseeing the Foundation's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of these financial statements is located at the Auditing and Assurance Standards Board website at:

https://auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our independent auditor's report.



William Buck (SA)
ABN 38 280 203 274



G.W. Martinella
Partner

Dated this 24th of July 2023.